Holen Sie sich die Stockscreener-App
5.70
7.32%
-0.45
Handel nachbörslich:
5.75
0.05
+0.88%
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference - Yahoo Finance
AURA: Late-stage oncology programs show strong safety, efficacy, and market potential, with key data ahead - TradingView
Aura's Bel-sar — One Asset, Multiple Oncology Opportunities - RTTNews
Aura Biosciences (AURA) officer granted RSUs and 112,661-share option - Stock Titan
Aura Biosciences (AURA) officer receives RSU and option grants - Stock Titan
Large equity awards to Elisabet de los Pinos at Aura Biosciences (AURA) - Stock Titan
Aura Biosciences (AURA) CTO receives new stock option and RSU awards - Stock Titan
Aura Biosciences (AURA) grants stock options and RSUs to its CMO - Stock Titan
Aura Biosciences (AURA) SVP awarded 80,472 options and 44,528 RSUs - Stock Titan
Aura Biosciences Posts Q2 Cash Surge - AOL.com
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Recap: Is Aura Biosciences Inc in a long term uptrend2025 Technical Overview & Risk Managed Investment Strategies - baoquankhu1.vn
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech Gem With 235% Potential Upside - DirectorsTalk Interviews
AURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aura Biosciences plans fireside chats at three March healthcare events - Stock Titan
Update Recap: Is Aura Biosciences Inc stock undervalued right now2025 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (AURA) - Stock Traders Daily
Aura Biosciences, Inc. (AURA) Stock Analysis: Assessing a Potential 300% Upside in Biotech Innovation - DirectorsTalk Interviews
Aura Biosciences Expands Evidence With New Patient-Reported Outcome Study in Eye Cancer - TipRanks
Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, Aura Biosciences, Seagen, IDEAYA, Ascentage Pharma - Barchart.com
Aura Biosciences (NASDAQ:AURA) SVP Amy Elazzouzi Sells 8,549 Shares - MarketBeat
What makes Aura Biosciences (AURA) a new buy stock - MSN
Are Medical Stocks Lagging Assertio (ASRT) This Year? - Bitget
Can Aura Biosciences Inc. outperform under higher oil prices2025 Investor Takeaways & Growth Focused Entry Point Reports - mfd.ru
Is Aura Biosciences Inc. exposed to currency risksBreakout Watch & Growth Oriented Trade Recommendations - mfd.ru
What Makes Aura Biosciences (AURA) a New Buy Stock - Yahoo Finance
Aura Biosciences, Inc. (AURA) Stock Analysis: Unpacking a 259% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Big Picture: Can Aura Biosciences Inc benefit from deglobalizationQuarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (AURA) Movement - Stock Traders Daily
Should you buy the dip on Aura Biosciences Inc.2025 Valuation Update & Weekly High Conviction Ideas - mfd.ru
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech Player with a Potential Upside of 237% - DirectorsTalk Interviews
AURA Should I Buy - Intellectia AI
Discipline and Rules-Based Execution in AURA Response - Stock Traders Daily
Guidance Update: Can Aura Biosciences Inc deliver alphaTrade Entry Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Aura Biosciences, Inc. (AURA): Investor Outlook with a Remarkable 257.93% Potential Upside - DirectorsTalk Interviews
Following a 29% decline over last year, recent gains may please Aura Biosciences, Inc. (NASDAQ:AURA) institutional owners - simplywall.st
WhiteFiber Inc (WYFI) Announces $200 Million Convertible Notes Offering, Shares Drop 5.5% - intellectia.ai
WhiteFiber, T1 Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
We're Keeping An Eye On Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate - Yahoo Finance
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket - Benzinga
Los Pinos Elisabet De Sells 16,928 Shares of Aura Biosciences (NASDAQ:AURA) Stock - Defense World
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com - Investing.com Australia
Behavioral Patterns of AURA and Institutional Flows - Stock Traders Daily
Top Executive Makes a Big Move With Aura Biosciences Stock - TipRanks
Aura Biosciences CEO de los Pinos sells $82k in stock - Investing.com Canada
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock - Investing.com
Big Picture: How does Aura Biosciences Inc perform in inflationary periodsMarket Risk Analysis & Safe Entry Point Alerts - baoquankhu1.vn
Is Postal Realty Trust Inc. in a long term uptrendWeekly Profit Summary & Daily Growth Stock Tips - bollywoodhelpline.com
RSI Check: Why hedge funds are buying Aura Biosciences Inc stockPortfolio Return Summary & Verified Chart Pattern Signals - Bộ Nội Vụ
Profit Recap: Is Aura Biosciences Inc in a long term uptrend2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Update Recap: Can Aura Biosciences Inc. stock continue upward trendPrice Action & Risk Controlled Swing Alerts - Bộ Nội Vụ
Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer - BioSpace
Pediatrix Medical Group, Inc. (NYSE:MD) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):